428 related articles for article (PubMed ID: 28129976)
1. Evaluation of a series of 2-napthamide derivatives as inhibitors of the drug efflux pump AcrB for the reversal of antimicrobial resistance.
Wang Y; Mowla R; Guo L; Ogunniyi AD; Rahman T; De Barros Lopes MA; Ma S; Venter H
Bioorg Med Chem Lett; 2017 Feb; 27(4):733-739. PubMed ID: 28129976
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological activity evaluation of novel 4-subtituted 2-naphthamide derivatives as AcrB inhibitors.
Wang Y; Mowla R; Ji S; Guo L; De Barros Lopes MA; Jin C; Song D; Ma S; Venter H
Eur J Med Chem; 2018 Jan; 143():699-709. PubMed ID: 29220791
[TBL] [Abstract][Full Text] [Related]
3. Kinetic analysis of the inhibition of the drug efflux protein AcrB using surface plasmon resonance.
Mowla R; Wang Y; Ma S; Venter H
Biochim Biophys Acta Biomembr; 2018 Apr; 1860(4):878-886. PubMed ID: 28890187
[TBL] [Abstract][Full Text] [Related]
4. Molecular basis for inhibition of AcrB multidrug efflux pump by novel and powerful pyranopyridine derivatives.
Sjuts H; Vargiu AV; Kwasny SM; Nguyen ST; Kim HS; Ding X; Ornik AR; Ruggerone P; Bowlin TL; Nikaido H; Pos KM; Opperman TJ
Proc Natl Acad Sci U S A; 2016 Mar; 113(13):3509-14. PubMed ID: 26976576
[TBL] [Abstract][Full Text] [Related]
5. Structural optimization of natural product nordihydroguaretic acid to discover novel analogues as AcrB inhibitors.
Wang Y; Alenzy R; Song D; Liu X; Teng Y; Mowla R; Ma Y; Polyak SW; Venter H; Ma S
Eur J Med Chem; 2020 Jan; 186():111910. PubMed ID: 31801655
[TBL] [Abstract][Full Text] [Related]
6. Chlorpromazine and Amitriptyline Are Substrates and Inhibitors of the AcrB Multidrug Efflux Pump.
Grimsey EM; Fais C; Marshall RL; Ricci V; Ciusa ML; Stone JW; Ivens A; Malloci G; Ruggerone P; Vargiu AV; Piddock LJV
mBio; 2020 Jun; 11(3):. PubMed ID: 32487753
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of novel 4-substituted quinazoline-2-carboxamide derivatives targeting AcrB to reverse the bacterial multidrug resistance.
Gu X; Pisoni LA; Wang Y; Song D; Sykes MJ; Qin Y; Semple SJ; Polyak SW; Venter H; Ma S
Bioorg Chem; 2020 Dec; 105():104394. PubMed ID: 33120321
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and evaluation of a series of 5-methoxy-2,3-naphthalimide derivatives as AcrB inhibitors for the reversal of bacterial resistance.
Jin C; Alenazy R; Wang Y; Mowla R; Qin Y; Tan JQE; Modi ND; Gu X; Polyak SW; Venter H; Ma S
Bioorg Med Chem Lett; 2019 Apr; 29(7):882-889. PubMed ID: 30755336
[TBL] [Abstract][Full Text] [Related]
9. Reversal of the Drug Binding Pocket Defects of the AcrB Multidrug Efflux Pump Protein of Escherichia coli.
Soparkar K; Kinana AD; Weeks JW; Morrison KD; Nikaido H; Misra R
J Bacteriol; 2015 Oct; 197(20):3255-64. PubMed ID: 26240069
[TBL] [Abstract][Full Text] [Related]
10. Discovery of multidrug efflux pump inhibitors with a novel chemical scaffold.
Green AT; Moniruzzaman M; Cooper CJ; Walker JK; Smith JC; Parks JM; Zgurskaya HI
Biochim Biophys Acta Gen Subj; 2020 Jun; 1864(6):129546. PubMed ID: 32032658
[TBL] [Abstract][Full Text] [Related]
11. Metabolomics Reveal Potential Natural Substrates of AcrB in Escherichia coli and Salmonella enterica Serovar Typhimurium.
Wang-Kan X; Rodríguez-Blanco G; Southam AD; Winder CL; Dunn WB; Ivens A; Piddock LJV
mBio; 2021 Mar; 12(2):. PubMed ID: 33785633
[TBL] [Abstract][Full Text] [Related]
12. Design and structural optimization of novel 2H-benzo[h]chromene derivatives that target AcrB and reverse bacterial multidrug resistance.
Wang Y; Alenazy R; Gu X; Polyak SW; Zhang P; Sykes MJ; Zhang N; Venter H; Ma S
Eur J Med Chem; 2021 Mar; 213():113049. PubMed ID: 33279291
[TBL] [Abstract][Full Text] [Related]
13. Binding site feature description of 2-substituted benzothiazoles as potential AcrAB-TolC efflux pump inhibitors in E. coli.
Yilmaz S; Altinkanat-Gelmez G; Bolelli K; Guneser-Merdan D; Ufuk Over-Hasdemir M; Aki-Yalcin E; Yalcin I
SAR QSAR Environ Res; 2015; 26(10):853-71. PubMed ID: 26559566
[TBL] [Abstract][Full Text] [Related]
14. A fluorescent microplate assay quantifies bacterial efflux and demonstrates two distinct compound binding sites in AcrB.
Iyer R; Ferrari A; Rijnbrand R; Erwin AL
Antimicrob Agents Chemother; 2015 Apr; 59(4):2388-97. PubMed ID: 25645845
[TBL] [Abstract][Full Text] [Related]
15. Phytochemicals increase the antibacterial activity of antibiotics by acting on a drug efflux pump.
Ohene-Agyei T; Mowla R; Rahman T; Venter H
Microbiologyopen; 2014 Dec; 3(6):885-96. PubMed ID: 25224951
[TBL] [Abstract][Full Text] [Related]
16. Comparative reassessment of AcrB efflux inhibitors reveals differential impact of specific pump mutations on the activity of potent compounds.
Schuster S; Vavra M; Wirth DAN; Kern WV
Microbiol Spectr; 2024 Feb; 12(2):e0304523. PubMed ID: 38170977
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of benzochromene derivatives as AcrB inhibitors for the reversal of bacterial multidrug resistance.
Guo T; Chen Y; Chen W; Semple SJ; Gu X; Polyak SW; Sun G; Venter H; Ma S
Eur J Med Chem; 2023 Mar; 249():115148. PubMed ID: 36709649
[TBL] [Abstract][Full Text] [Related]
18. Identification of natural compound inhibitors for multidrug efflux pumps of Escherichia coli and Pseudomonas aeruginosa using in silico high-throughput virtual screening and in vitro validation.
Aparna V; Dineshkumar K; Mohanalakshmi N; Velmurugan D; Hopper W
PLoS One; 2014; 9(7):e101840. PubMed ID: 25025665
[TBL] [Abstract][Full Text] [Related]
19. [Reserpine Is the New Addition into the Repertoire of AcrB Efflux Pump Inhibitors].
Shaheen A; Afridi WA; Mahboob S; Sana M; Zeeshan N; Ismat F; Mirza O; Iqbal M; Rahman M
Mol Biol (Mosk); 2019; 53(4):674-684. PubMed ID: 31397441
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanism of MBX2319 inhibition of Escherichia coli AcrB multidrug efflux pump and comparison with other inhibitors.
Vargiu AV; Ruggerone P; Opperman TJ; Nguyen ST; Nikaido H
Antimicrob Agents Chemother; 2014 Oct; 58(10):6224-34. PubMed ID: 25114133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
